Abstract
Major finding: F1174L-mutated ALK shows reduced sensitivity to crizotinib inhibition.
Mechanism: The F1174L mutation enhances the ATP-binding affinity of ALK.
Impact: Patients with F1174L-mutated ALK may benefit from higher crizotinib doses.
This content is only available via PDF.
©2011 American Association for Cancer Research.
2011